Ignite Creation Date:
2024-05-05 @ 9:20 PM
Last Modification Date:
2024-10-26 @ 10:03 AM
Study NCT ID:
NCT00869999
Status:
COMPLETED
Last Update Posted:
2014-10-27
First Post:
2009-03-25
Brief Title:
Everolimus Plus Rituximab for RelapsedRefractory Diffuse Large B Cell Lymphoma
Sponsor:
Massachusetts General Hospital
Organization:
Massachusetts General Hospital
Organization Data
Organization:
Massachusetts General Hospital
Class:
OTHER
Study ID:
09-002
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Massachusetts General Hospital
Lead Sponsor Class:
OTHER
Responsible Party:
Jeremy Abramson MD
Responsible Party Title:
Director Lymphoma Program
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Massachusetts General Hospital
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Novartis | INDUSTRY |
| Beth Israel Deaconess Medical Center | OTHER |
| Dana-Farber Cancer Institute | OTHER |